Ypsomed's YpsoMate autoinjector enters market with Terumo and Mylan

Ypsomed's YpsoMate autoinjector achieved its first commercial market entry, with Terumo Corporation filling its PLAJEX syringe with the drug Hulio (adalimumab) and assembling it with the YpsoMate. First commercial deliveries from Switzerland to Japan are completed.

“For Ypsomed, this not only means the successful commercialisation of Hulio ® project launched in 2013, but also the first commercial market entry of the YpsoMate autoinjector.”ypsomed.com

• 1 source
• ypsomed.comFirst market entry of YpsoMate autoinjector from Ypsomed - YpsomedDec 7, 2018

Summarized from public sources; check the original articles before acting on it.